National Institute for Health and Clinical Excellence

Single Health Technology Appraisal (STA)

Trastuzumab for the treatment of HER-2 positive advanced gastric cancer

Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)

Comment 1: the draft remit

<table>
<thead>
<tr>
<th>Section</th>
<th>Consultees</th>
<th>Comments</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appropriateness</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Wording</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Timing Issues</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Additional comments on the draft remit</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
</tbody>
</table>
## Comment 2: the draft scope

<table>
<thead>
<tr>
<th>Section</th>
<th>Consultees</th>
<th>Comments</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background information</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>The technology/intervention</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Population</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Comparators</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Outcomes</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Economic analysis</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Equality</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Other considerations</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Questions for consultation</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
<tr>
<td>Additional comments on the draft scope.</td>
<td>NCRI/RCP/RCR/ACP/JCCO</td>
<td>proposed appraisal is premature for scoping</td>
<td>Comment noted. It was agreed at the scoping workshop that early consideration of this topic would enable the Institute to issue timely guidance following marketing authorisation.</td>
</tr>
<tr>
<td>Comments on matrix of consultees &amp; commentators</td>
<td>N/A</td>
<td>No comments received</td>
<td>No actions required</td>
</tr>
</tbody>
</table>
The following consultees/commentators indicated that they had no comments on the draft remit and/or the draft scope

1. Roche Products
2. NHS Quality Improvement Scotland
3. NPHS Wales
4. The Research Institute for the Care of Older People
5. Sanofi-aventis
6. Marie Curie Cancer Care
7. Royal Pharmaceutical Society